Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kura Oncology Inc KURA

Healthcare Biotechnology
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that... see more

Recent & Breaking News (NDAQ:KURA)

Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock

GlobeNewswire June 18, 2019

Kura Oncology Announces Commencement of Public Offering of Common Stock

GlobeNewswire June 18, 2019

Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in Peripheral T-Cell Lymphoma

GlobeNewswire June 14, 2019

Kura Oncology to Present at Bank of America Merrill Lynch Health Care Conference

GlobeNewswire May 8, 2019

Kura Oncology Reports First Quarter 2019 Financial Results and Highlights Upcoming Milestones

GlobeNewswire May 7, 2019

Kura Oncology to Report First Quarter 2019 Financial Results

GlobeNewswire April 30, 2019

Kura Oncology Identifies Farnesylated Proteins Associated with CXCL12 Expression, Potential Biomarker of Clinical Benefit from Tipifarnib in Lymphoma Indications

GlobeNewswire April 2, 2019

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire March 6, 2019

Kura Oncology Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 5, 2019

Kura Oncology Announces FDA Clearance of Investigational New Drug Application for Menin-MLL Inhibitor KO-539

GlobeNewswire March 5, 2019

Kura Oncology to Present at SVB Leerink Global Healthcare Conference

GlobeNewswire February 20, 2019

Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression

GlobeNewswire January 18, 2019

Kura Oncology to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2019

Kura Oncology Announces Proof of Concept in Angioimmunoblastic T-Cell Lymphoma, Validation of CXCL12 as a Therapeutic Target of Tipifarnib in Peripheral T-Cell Lymphoma

GlobeNewswire December 2, 2018

Report: Exploring Fundamental Drivers Behind J.B. Hunt Transport Services, Kura Oncology, National Beverage, Benefitfocus, PTC Therapeutics, and Walgreens Boots Alliance — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 30, 2018

Kura Oncology Announces New Patent for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

GlobeNewswire November 28, 2018

Kura Oncology Adds Commercial Veteran Mary Szela to Board of Directors

GlobeNewswire November 8, 2018

Kura Oncology to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 6, 2018

Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update

GlobeNewswire November 5, 2018

Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas

GlobeNewswire November 5, 2018